2023 ASCO 先见｜黑色素瘤领域中国重磅研究一览

标题：Temozolomide plus cisplatin versus toripalimab (anti-PD-1) as adjuvant therapy in resected mucosal melanoma.

报告人：郭军

单位：北京大学肿瘤医院

标题：Efficacy and safety of tunlametinib in patients with advanced NRAS-mutant melanoma: A multicenter, open-label, single-arm, phase 2 study.

报告人：斯璐

单位：北京大学肿瘤医院

标题：NeoPlus: A phase II study of neoadjuvant lenvatinib and pembrolizumab in resectable mucosal melanoma.

报告人：毛丽丽

单位：北京大学肿瘤医院

标题：Identification of RPTOR mutation as a novel predictor of efficacious immunotherapy in melanoma.

报告人: 李永召

单位：石家庄市人民医院

标题：Early safety and efficacy from a phase I clinical study of TWP-101, a novel CD137 agonist antibody, in patients with advanced melanoma and urothelial carcinoma.

报告人：郭军

单位：北京大学肿瘤医院

标题：Updated safety and efficacy results from the phase I study of either LBL-007 (an anti-LAG-3 antibody) in combination with toripalimab (an anti-PD-1 antibody) or LBL-007 in combination with toripalimab and axitinib in patients with advanced melanoma.

报告人：白雪

单位：北京大学肿瘤医院

标题：Phase II clinical trial of camrelizumab combined with famitinib for advanced acral and mucosal melanoma.

报告人：毛丽丽

单位：北京大学肿瘤医院

标题：Analysis of overall survival (OS) and progression-free survival (PFS) in the phase 1b clinical trial of anti–PD-1 ab (toripalimab) plus intrahepatic injection of OrienX010 in stage IV melanoma with liver metastases.

报告人：崔传亮

单位：北京大学肿瘤医院

标题：Camrelizumab combined with anlotinib and nab-paclitaxel in patients with untreated advanced mucosal melanoma: A single-arm, multicenter, exploratory study.

报告人：吴荻

单位：吉林大学第一医院肿瘤中心